PAVmed Inc. (NASDAQ:PAVM) Short Interest Down 27.0% in December
by Scott Moore · The Cerbat GemPAVmed Inc. (NASDAQ:PAVM – Get Free Report) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 427,310 shares, a drop of 27.0% from the November 30th total of 585,084 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily trading volume, of 322,686 shares, the days-to-cover ratio is presently 1.3 days. Based on an average daily trading volume, of 322,686 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.6% of the shares of the company are short sold.
Wall Street Analysts Forecast Growth
PAVM has been the subject of several recent research reports. Ascendiant Capital Markets lowered their price target on shares of PAVmed from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, December 10th. Zacks Research lowered shares of PAVmed from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.00.
View Our Latest Research Report on PAVM
Institutional Inflows and Outflows
An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC increased its position in shares of PAVmed Inc. (NASDAQ:PAVM – Free Report) by 392.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the period. Jane Street Group LLC owned 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. Institutional investors and hedge funds own 19.93% of the company’s stock.
PAVmed Price Performance
Shares of NASDAQ PAVM traded down $0.02 during midday trading on Wednesday, reaching $0.22. 1,197,376 shares of the company traded hands, compared to its average volume of 290,094. The company has a market cap of $6.53 million, a price-to-earnings ratio of -0.39 and a beta of 1.09. The stock has a 50-day moving average price of $0.35 and a 200 day moving average price of $0.45. PAVmed has a 52 week low of $0.21 and a 52 week high of $0.90.
Shares of PAVmed are scheduled to reverse split on the morning of Friday, January 2nd. The 1-30 reverse split was announced on Tuesday, December 30th. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, December 31st.
PAVmed Company Profile
PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.
Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.